Company* (Symbol)




Status (Date)


Allos Therapeutics Inc. (ALTH)


Synthetic allosteric modifier of hemoglobin that noncovalently binds to hemoglobin, increasing oxygen delivery to hypoxic tissue

Recurrent malignant glioma

Phase Ib/II study of RSR13 administered with BCNU (carmustine) chemotherapy is under way (1/16)

AltaRex Corp. (Canada; TSE:AXO; OTC BB:ALRXF)


Modified murine monoclonal antibody that binds to CA125 cancer antigen

Ovarian cancer

Phase II trial final results indicated the compound increases survival (1/3)

Antisoma plc (UK; LSE:ASM; ASOM)


Injectable radiolabeled antibody fragment used in combination with external beam radiotherapy


Company started the first clinical study (1/29)

Atrix Laboratories Inc. (ATRX)


Leuprolide acetate for subcutaneous depot injection

Advanced prostate cancer

Enrollment began for a Phase III trial (1/29)

AVI BioPharma Inc. (AVII)


Nontoxic therapeutic cancer vaccine, which elicits a highly specific immune response to human chorionic gonadotropin

Colorectal cancer

Company initiated a Phase III trial (1/4)

British Biotech plc (UK; LSE:BBG; BBIOY)


Oral matrix metalloproteinase inhibitor

Small-cell lung cancer

Company completed a clinical trial of marimastat (1/19)

Cell Genesys Inc. (CEGE)


Cancer vaccine comprised of tumor cells that have been irradiated and genetically modified to secrete granulocyte macrophage-colony stimulating factor

Pancreatic cancer

Three of eight patients who received a higher dose of GVAX in combination with surgery remained disease-free and alive at 38, 35 and 33 months after diagnosis; results were published in the Journal of Clinical Oncology (1/2)

Cell Therapeutics Inc. (CTIC)


Arsenic trioxide injection

Multiple myeloma

Company initiated the first of several company-sponsored multicenter clinical trials with Trisenox injection (1/31)

Genta Inc. (GNTA)


Antisense compound; synthetic DNA strands that bind to mRNA for the bc12 gene

Acute myeloid leukemia and chronic lymphocytic leukemia

Company initiated two clinical trials in relapsed patients (1/19)

Immuno-Designed Molecules SA* (France)


Cellular vaccine composed of dendritophages loaded in vitro with specific tumor antigens derived from cancer cell extracts, called lysates

Malignant melanoma

Company launched a Phase II trial (1/29)

Inex Pharmaceuticals Corp. (Canada; INEX)

Onco TCS

Therapeutic consisting of vincristine encapsulated in Inex's transmembrane carrier systems drug delivery technology

Non-Hodgkin's lymphoma

Company began screening patients for its pivotal Phase II/III trial evaluating Onco TCS (1/31)

IntraBiotics Pharmaceuticals Inc. (IBPI)

Protegrin IB-367

A rinse; synthetically derived analogue of naturally occurring protegrins


Company completed patient enrollment in its Phase III trial (1/16)

Ligand Pharmaceuticals Inc. (LGND)


Denileukin difitox; fusion protein consisting of fragment of diphtheria toxin genetically fused to interleukin-2

Persistant or refractory cutaneous T-cell lymphoma

Results showing Ontak induces partial and complete responses in patients were published in the Journal of Clinical Oncology (1/22)

NeoRx Corp. (NERX)

Pretarget technology

Designed to deliver therapeutic products to tumor sites

Non-Hodgkin's lymphoma

Company began a Phase I trial (1/10)

Peregrine Pharmaceuticals Inc. (PPHM)


Tumor necrosis therapy; chimeric monoclonal anti-body that targets DNA-associated histone antigens, labeled with I-131

Recurrent or unresectable malignant glioma

Phase II trial indicated median time to progression of about 14 weeks, a 75% increase over historical data for the 16 evaluable patients (1/9)

Pharmacyclics Inc. (PCYC)


Motexafin gadolinium injection

Brain metastases

Phase III trial reached 90% enrollment and the compound was found to be safe (1/9)

Progenics Pharmaceuticals Inc. (PGNX)


Cancer vaccine designed to stimulate a patient's immune system to control or eradicate residual cancer cells after surgery, radiation or chemotherapy


Trial results published in Clinical Cancer Research showed the vaccine to be free of significant toxicity and that it induced antibodies against two different targets on cancer cells (1/24)

SciClone Pharmaceuticals Inc. (SCLN)


Immune system enhancer used in combination with radio frequency abalation

Hepatocellular carcinoma

Company initiated a Phase II study (1/8)


Alexion Pharmaceuticals Inc. (ALXN)

Pexelizumab (formerly 5G1.1-SC)

An anti-inflammatory C5 inhibitor monoclonal antibody fragment

For patients undergoing cardiac surgery with cardiopulmonary bypass

Phase IIb results showed pexelizumab suppressed complement in CPB patients and appears to be safe and well tolerated; pexelizumab also reduced the composite incidence of death or myocardial infarction by 41% at 30 days (1/23)

Alliance Pharmaceutical Corp. (ALLP)


Perflubron emulsion; intravascular oxygen carrier or blood substitute that carries oxygen to tissues through the bloodstream

Patients undergoing cardiac bypass

Company stopped enrollment in Phase III due to an imbalance in adverse events, particularly the incidence of stroke (1/9)

Avant Immunotherapeutics Inc. (AVAN)


Soluble form of complement receptor 1, designed to inhibit complement proteins

For infants undergoing high-risk cardiac surgery using cardiopulmonary bypass

Company began a Phase IIb trial (1/4)

Chiron Corp. (CHIR)


Recombinant fibroblast growth factor-2 protein

Peripheral artery disease

Phase II results presented at the American Heart Association Scientific Conference on Therapeutic Angiogenesis and Myocardial Laser Revascularization indicated the primary efficacy endpoint, peak walking time at day 90, showed positive trends, but did not reach statistical significance (1/27)

CV Therapeutics Inc. (CVTX)


Part of pFOX (partial

Stable angina fatty acid oxidation)

Company plans to enroll an additional 186 patients in a 462-patient Phase III study (1/5)

IDEC Pharmaceuticals Inc. (IDPH)


Humanized anti-CD154 monoclonal antibody

Chronic, refractory immune thrombocytopenic purpura

Company initiated a Phase II trial (1/4)

Neuron Therapeutics Inc.*


Oxygenated fluorocarbon nutrient emulsion

Severe ischemic stroke

Company initiated a Phase I trial (1/29)


Alexion Pharmaceuticals Inc. (ALXN)


Anti-inflammatory C5 inhibitor monoclonal antibody

Rheumatoid arthritis

Phase II interim results showed the study met its primary end-point (1/29)

AlphaRx Inc. (Canada; OTC BB: AHRX)


Indomethacin; nonsteroidal anti-inflammatory drug


Company initiated a trial to assess the drug's pharmacokinetics, rate of onset, gastrointestinal irritation properties and patient tolerance (1/3)

Biogen Inc. (BGEN)

Avonex (FDA-approved)

Interferon beta-1a

Secondary progressive multiple sclerosis

Company's IMPACT study achieved its primary endpoint, reducing the progression of disability by 27% vs. placebo (1/16)

NicOx SA (France; Nouveau Marche:NICOX) and AstraZeneca plc (UK)


NO-NSAID compound

Pain and inflammation

Companies initiated Phase II trials (1/24)

Scios Inc. (SCIO)


Novel oral p38 kinase inhibitor

Rheumatoid arthritis

Phase I data indicated the drug is well tolerated in healthy volunteers (1/24)

SkyePharma plc (UK; LSE:SKP; SKYE)


Sustained-release morphine formulation using Skye-Pharma's DepoFoam injection technology

Moderate to acute post-operative pain

Company started Phase III trials involving 750 patients in the U.S. and Europe (1/10)

Titan Pharmaceuticals Inc. (AMEX:TTP)


Cell therapy product that uses human retinal pigmented epithelial cells that secrete dopamine

Parkinson's disease

Company began treatment in the first cohort of patients receiving Spheramine in a Phase I/II study (1/25)

Vertex Pharmaceuticals Inc. (VRTX)


Small-molecule inhibitor of p38 MAP kinase, which regulates the production of tumor necrosis factor-alpha and interleukin-1

Rheumatoid arthritis

Company began a Phase II trial (1/4)


Insmed Inc. (INSM)


Oral insulin sensitizer used in combination with sulfonylurea

Type II diabetes

Full analysis of a Phase II trial showed patients experienced statistically significant improvement in glycohemoglobin compared to those receiving sulfonylurea alone (1/5)


Antex Biologics Inc. (AMEX:ANX)


Campylobacter infection vaccine

Campylobacter infection

Phase II results indicated the compound produces significant immune responses that correlate with protection against disease (1/9)

Corixa Corp. (CRXA)


Synthetic adjuvant used in combination with AgB vaccine

Hepatitis B virus

Company initiated a Phase III trial (1/11)

CV Technologies Inc. (Canada; CDNX:CVQ)


A multicomponent phytopharmaceutical

Cold and flu

Company started a second Phase II trial (1/18)

Enzo Biochem Inc. (NYSE:ENZ)


HIV-1 gene medicine product


Company said it achieved successful results in its Phase I trial and is planning to extend the study (1/11)

MediGene AG* (Germany)

Polyphenon E

Antioxidative, anti-inflammatory and blocks virus binding to the cell; has antitumor activity

Genital warts caused by human papillomavirus

Company initiated a Phase III trial (1/4)

SciClone Pharmaceuticals Inc. (SCLN)


Subcutaneous injectable immune system enhancer

Hepatitis C

Company initiated a pivotal Phase III trial in the U.S. (1/10)

Stressgen Biotechnologies Corp. (Canada; TSE:SSB)


Recombinant fusion product composed of heat shock protein 65 from Mycobacterium bovis BCG and the protein E7, derived from the human papillomavirus dysplasia

Genital warts caused by human papillomavirus

Company initiated a Phase II trial (1/9)

Trimeris Inc. (TRMS) and F. Hoffmann-La Roche Ltd.(Switzerland)

T-20 and T-1249

Members of a new class of anti-HIV drugs called fusion inhibitors


Early study results indicate the drugs could offer patients resistant to other products an option in slowing the progression of the disease (1/29)


Adolor Corp. (ADLR)

ADL 8-2698

Orally administered, gutselective narcotic antagonist

Opioid bowel dysfunction

Phase II results showed the compound mitigates the severe opioid-induced bowel dysfunction in patients taking narcotics without interfering with the narcotics' analgesic effects (1/18)

AeroGen Inc. (AEGN)


Albuteral inhaler


Company entered Phase II trials (1/9)

Alteon Inc. (AMEX:ALT)


Advanced glycosylation endproduct crosslink breaker

Advanced glycosylation endproduct crosslink formation

Phase IIa trial results indicated patients experienced a statistically significant reduction in arterial pulse pressure and a clinically relevant increase in larger artery compliance (1/3)

Amarillo Biosciences Inc. (OTC BB:AMAR)


Oral interferon-alpha

Sjogren's syndrome

Company completed its second Phase III trial, which noted an increase in saliva production and improvements in oral symptoms (1/5)

Atrix Laboratories Inc. (ATRX)


Dapsone topical gel in SMP technology


Company plans to begin the first of its Phase III studies (1/3)

Avant Immunotherapeutics Inc. (AVAN)


Therapeutic vaccine against endogenous cholesterylester transfer protein (CETP), a key intermediary in the distribution of cholesterol between high-density lipoprotein and low-density lipoprotein

To treat patients with low levels of HDL cholesterol

Phase I trial indicated the compound is well tolerated (1/9)

Biogen Inc. (BGEN)


Humanized monoclonal antibody directed against the alpha-4-beta-1 integrin expressed in certain white blood cells

Multiple sclerosis and Crohn's disease

Phase II results showed Antegren achieved its endpoint of reduction of new gadolinium-enhancing lesions in multiple sclerosis; Antegren also reached its end-points of induction of remission in Crohn's disease (1/23)

BioMarin Pharmaceutical Inc. (BMRN) and Genzyme General (GENZ)


Enzyme replacement therapy; recombinant alpha-L-iduronidase

Mucopolysacch-aridosis I (MPS-1)

Clinical trial results reported in the New England Journal of Medicine show the therapeutic has potential to alleviate the primary symptoms of MPS-1; data also indicate the therapy is well tolerated and effective (1/18)

Cerus Corp. (CERS) and Baxter Healthcare Corp. (NYSE:BAX)

Intercept Platelet System

A system to inactivate bacteria, viruses and other pathogens and white blood cells in platelets intended for transfusion

To inactivate viruses, bacteria and other pathogens

Companies completed enrollment in the 600-patient Phase III trial (1/25)

Endovasc Ltd. (OTC BB:ENDV)


Developed using liposome drug delivery technology to encapsulate prostaglandin E-1, a potent vasodilator, platelet inhibitor and anti-thrombotic

Critical limb ischemia

Company completed Phase I trials that showed the drug to be well tolerated and safe (1/16)

Esperion Therapeutics Inc. (ESPR)


Large unilamellar vesicles; spherical particles comprised of naturally occurring lipids that recirculate through arteries

Atherosclerosis and low HDL-C

Company initiated a Phase IIa program (1/9)

Genmab A/S (Denmark; CSE:GEN)


Fully human antibody

Severe psoriasis

Company initiated a Phase II trial (1/9)

IDEC Pharmaceuticals Inc. (IDPH)


A primatized anti-CD80 monoclonal antibody

Moderate to severe psoriasis

Company initiated a Phase II trial (1/11)

IDEC Pharmaceuticals Inc. (IDPH)


Humanized anti-CD154 moncolonal antibody


Company initiated a Phase II trial (1/29)

Incara Pharmaceuticals Corp. (INCR)


Subcutaneously administered ultra-low molecular weight heparin

Ulcerative colitis

Patients are now being enrolled and treated in a pivotal Phase II/III study of OP2000 (1/29)

Inspire Pharmaceuticals Inc. (ISPH)


P2Y(2) receptor agonist

Dry eye syndrome

Company initiated Phase III trials (1/9)

Interneuron Pharmaceuticals Inc. (IPIC) and Pfizer Inc. (NYSE:PFE)


Compound that potentiates action of the neurotransmitter gamma amino butyric acid (partial agonist)

Anxiety disorder

Companies initiated Phase II testing (1/16)

Labopharm Inc. (Canada; TSE:DDS)


Leval buterol HCL


Phase II results demonstrated significant improvement in breathing compared to placebo (1/9

Orthologic Corp. (OLGC)


Synthetically manufactured peptide

Fracture healing

Company completed enrollment in its Phase I/II trial (1/18)

Protein Design Labs Inc. (PDLI)

SMART Anti-Gamma Interferon


Crohn's disease

Company began a Phase I/II trial (1/10)

Vivus Inc. (VVUS)


Formulation of alprostadil, a naturally occurring vasodilating agent

Female sexual dysfunction

Company initiated enrollment in its Phase II study (1/23)